Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2010 2
2011 5
2012 5
2014 4
2015 10
2016 9
2017 10
2018 16
2019 22
2020 17
2021 19
2022 12
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Prevalence and outcome of occult giant cell arteritis.
Moreel L, Betrains A, De Langhe E, Blockmans D, Vanderschueren S. Moreel L, et al. Among authors: de langhe e. Eur J Intern Med. 2024 Apr 29:S0953-6205(24)00179-1. doi: 10.1016/j.ejim.2024.04.019. Online ahead of print. Eur J Intern Med. 2024. PMID: 38688812 No abstract available.
Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.
Khanna D, Kramer F, Höfler J, Ghadessi M, Sandner P, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, De Langhe E, Hachulla E, Ishii T, Ishikawa O, Johnson SR, Riccieri V, Schiopu E, Silver RM, Smith V, Stagnaro C, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Distler O. Khanna D, et al. Among authors: de langhe e. Rheumatology (Oxford). 2024 Mar 9:keae150. doi: 10.1093/rheumatology/keae150. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38460548
Molecular characterisation of lupus low disease activity state (LLDAS) and DORIS remission by whole-blood transcriptome-based pathways in a pan-European systemic lupus erythematosus cohort.
Parodis I, Lindblom J, Barturen G, Ortega-Castro R, Cervera R, Pers JO, Genre F, Hiepe F, Gerosa M, Kovács L, De Langhe E, Piantoni S, Stummvoll G, Vasconcelos C, Vigone B, Witte T; PRECISESADS Clinical Consortium; Alarcón-Riquelme ME, Beretta L. Parodis I, et al. Among authors: de langhe e. Ann Rheum Dis. 2024 Feb 19:ard-2023-224795. doi: 10.1136/ard-2023-224795. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38373843 Free article.
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial.
Distler O, Allanore Y, Denton CP, Kuwana M, Matucci-Cerinic M, Pope JE, Atsumi T, Bečvář R, Czirják L, Hachulla E, Ishii T, Ishikawa O, Johnson SR, De Langhe E, Stagnaro C, Riccieri V, Schiopu E, Silver RM, Smith V, Steen V, Stevens W, Szücs G, Truchetet ME, Wosnitza M, Laapas K, Kramer F, Khanna D. Distler O, et al. Among authors: de langhe e. Lancet Rheumatol. 2023 Nov;5(11):e660-e669. doi: 10.1016/S2665-9913(23)00238-2. Lancet Rheumatol. 2023. PMID: 38251533 Clinical Trial.
Association of Combined Anti-Ro52/TRIM21 and Anti-Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway Activation.
Bettacchioli E, Saraux A, Tison A, Cornec D, Dueymes M, Foulquier N, Hillion S, Roguedas-Contios AM, Benyoussef AA, Alarcon-Riquelme ME, Pers JO, Devauchelle-Pensec V; PRECISESADS Clinical Consortium, and PRECISESADS Sjögren Consortium. Bettacchioli E, et al. Arthritis Rheumatol. 2024 May;76(5):751-762. doi: 10.1002/art.42789. Epub 2024 Feb 14. Arthritis Rheumatol. 2024. PMID: 38130019
High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome.
Desvaux E, Hemon P, Soret P, Le Dantec C, Chatzis L, Cornec D, Devauchelle-Pensec V; PRECISESADS clinical consortium; Elouej S, Duguet F, Laigle L, Poirier N, Moingeon P, Bretin S, Pers JO. Desvaux E, et al. J Autoimmun. 2023 Dec 18:103147. doi: 10.1016/j.jaut.2023.103147. Online ahead of print. J Autoimmun. 2023. PMID: 38114349
Systemic sclerosis and primary biliary cholangitis: Longitudinal data to determine the outcomes.
Lepri G, Airò P, Distler O, Andréasson K, Braun-Moscovici Y, Hachulla E, Balbir-Gurman A, De Langhe E, Rednic S, Ingegnoli F, Rosato E, Groseanu L, Ionescu R, Bellando-Randone S, Garzanova L, Beretta L, Bellocchi C, Moiseev S, Novikov P, Szabo I, Krasowska D, Codullo V, Walker UA, Manolaraki C, Guiducci S, Truchetet ME, Iannone F, Tofani L, Bruni C, Smith V, Cuomo G, Krusche M, Matucci-Cerinic M, Allanore Y. Lepri G, et al. Among authors: de langhe e. J Scleroderma Relat Disord. 2023 Oct;8(3):210-220. doi: 10.1177/23971983231155948. Epub 2023 Apr 4. J Scleroderma Relat Disord. 2023. PMID: 37744053
Autoantibodies against the melanoma differentiation-associated protein 5 in patients with dermatomyositis target the helicase domains.
Van Gompel E, Demirdal D, Fernandes-Cerqueira C, Horuluoglu B, Galindo-Feria A, Wigren E, Gräslund S, De Langhe E, Benveniste O, Notarnicola A, Chemin K, Lundberg IE. Van Gompel E, et al. Among authors: de langhe e. Rheumatology (Oxford). 2024 May 2;63(5):1466-1473. doi: 10.1093/rheumatology/kead400. Rheumatology (Oxford). 2024. PMID: 37572295
136 results